Advances in radiotherapy of brain tumors: Radiobiology versus reality

Journal of Clinical Neuroscience

Volumn 5, Issue 1, 1998, Pages 5-14

  Bampoe, Joseph ^a   Bernstein, Mark ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Benign brain tumors; Malignant glioma; Radiobiology; Radiotherapy

Indexed keywords

EID: 0002617773     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(98)90193-X     Document Type: Review

References (95)

1. Bouchard J. Radiation therapy of tumors and diseases of the nervous system. Philadelphia: Lea & Febiger, 1966: 244.
2. Kaye AH, LaidlawJD. Chemotherapy of gliomas. Curr Opin Neurol Neurosurg 1992; 5: 526-533.
3. Mahaley SM, Mettlin C, Natarajan N, Laws ER, Peace BB. National Survey of patterns of care for brain tumor patients. J Neurosurg 1989; 71: 826-836.
4. Zimmerman HM: Brain tumors: their incidence and classification in man and their experimental production. Ann NY Acad Sci 1969; 159: 337-359.
5. Leibel SA, Sheline GE. Radiation therapy for neoplasms of the brain. J Neurosurg 1987; 66: 1-22.
6. De Tribolet N, Sawamura Y Can brain tumors be cured? results of clinical trials. In: Crockard A, Hayward R, Hoff JT(eds). Neurosurgery: The Scientific Basis of Clinical Practice, 2nd Edn. Boston: Blackwell, 1992: 585-598.
7. Laperriere NL, Bernstein M. Radiotherapy for Brain Tumors. CA CancerJ Clin 1994; 44(2): 96-108.
8. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-1731.
9. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol 1993; 3: 255-268.
10. Shrieve DC, Loeffler JS. Advances in radiation therapy for brain tumors. Neurol Clin 1995; 13: 773-793.
11. Bernstein M, RutkaJ. Brain tumor protocols in North America. J Neurooncol 1993; 17: 231-251.
12. Bloom HJG: Intracranial tumors: Response and resistance to therapeutic endeavors, 1970-1980. Int J Radiat Oncol Biol Phys 1982; 8: 1083-1113.
13. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30: 907-911.
14. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16: 1405-1409.
15. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991; 64(4): 769-774.
16. Leibel SA, Sheline GE. Tolerance of the brain and spinal cord to conventional irradiation. In: Gutin PH, Leibel SA, Sheline GE (eds). Radiation Injury to the Nervous System. New York: Raven Press, 1991: 239-256.
17. Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980; 6: 1215-1228.
18. Van der Kogel A. Central nervous system radiation injury in small animal models. In: Gutin PH, Leibel SA, Sheline GE (eds). Radiation Injury to the Nervous System. New York: Raven Press, 1991: 91-111.
19. Pezner RD, Archambeau JO. Brain Tolerance Unit: a method to estimate risk of radiation brain injury for various dose schedules. Int J Radiat Oncol Biol Phys 1981; 7: 397-402.
20. Marks JE, Baglan RJ, Prassad SC, Blank WF. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 1981; 7: 243-252.
21. Barendson GW. Influence of fractionation on normal tissue tolerance. In: Gutin PH, Leibel SA, Sheline GE (eds). Radiation Injury to the Nervous System. New York: Raven Press, 1991: 57-67.
22. Kim JH, Hilaris B. Iodine 125 source in interstitial tumor therapy. Clinical and biological considerations. Am J Roentgenol Radium Ther Nuclear Med 1975; 123(1): 163-169.
23. Hall EJ. Cell Survival Curves, in Radiobiology for the Radiologist, 4th Edn. Philadelphia: JB Lippincott, 1994: 29-43.
24. Nelson DF, Curran WJ, Scott C et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72.0 Gy in 1.2 Gy BID fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 1993; 25(2): 193-207.
25. Freeman CR, Krischer J, Sanford RA et al. Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study: 8495. Cancer 1991; 68 (30): 474-481.
26. Mulhern RK, Heideman RL, Khatib ZA, Kovnar EH, Sanford RA, Kun LE. Quality of survival among children treated for brain stem glioma. Ped Neurosurg 1994; 20(4): 226-232.
27. Freeman CR, Bourgouin PM, Sanford RA, Cohen ME, Friedman HS, Kun LE. Long-term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group. Cancer 1996; 77(3): 555-562.
28. Packer RJ, Prados M, Phillips P et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study. Cancer 1996; 77(10): 2150-2156.
29. Leibel SA, Scott CB, Loeffler JS. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol 1994; 21(2): 198-219.
30. Begg AC, Hofland M, Van Glabekke, Bartelink H, Horiot JC. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC Cooperative Trial 22851. Semin Radiat Oncol 1992; 2: 22-25.
31. Horiot JC, Van den Bogaert W, Ang KK et al. European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. Front Radiat Ther Oncol 1988; 22: 149-161.
32. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996; 56(2): 405-411.
33. Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-l-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl) acetamide. Br J Cancer 1995; 72(4): 875-882.
34. Hall EJ. The oxygen effect and reoxygenation. In: Radiobiology for the Radiologist, 4th Edn. Philadelphia: JB Lippincott, 1994: 133-152.
35. Hall EJ. Radiosensitizers and bioreductive drugs. In: Radiobiology for the Radiologist, 4th Edn. Philadelphia: JB Lippincott, 1994: 165-181.
36. Urtasun RC, Band P, Chapman JD, Feldstein ML, Mielke B, Fryer C. Radiation and high dose metronidazole (Flagyl) in supratentorial glioblastoma. N Engl J Med 1976; 294: 1364-1367.
37. Deutsch M, Green SB, Strike TA et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1989; 16: 1389-1396.
38. Stadler B, Karcher KH, Kogelnik HD, Szepesi T. Misonidazole and irradiation in the treatment of high-grade astrocytomas: Further report of the Vienna Study Group. Int J Radiat Oncol Biol Phys 1984; 10: 1713-1717.
39. Fulton DS, Urtasun RC, Shin KH et al. Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys 1984; 10: 1709-1712.
40. Medical Research Council working party of misonidazole in gliomas: a study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grade 3 and 4 astrocytomas. Br J Radiol 1983; 56: 673-682.
41. EORTC Brain Tumor Group: Misonidazole in radiotherapy of supratentorial malignant gliomas in adult patients: A randomized double-blind study. Eur J Cancer 1983; 19: 39-42.
42. Nelson DF, Diener-West M, Weinstein AS et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys 1986; 12: 1793-1800.
43. Coleman CN, Riese N, Buswell L et al. Clinical trials of etanidazole (SR 2508) : RTOG and Joint Center for Radiation Therapy trials. In: Dewey WC, Edington M, Fry RJM, Hall EJ, Whitmore GF (eds). Radiation Research: A Twentieth-Century Perspective. San Diego: Academic Press, 1992: 595-600.
44. Newman HFV, Bleehen NM, Ward R, Worman P. Hypoxic cell radiosensitizers in the treatment of high-grade gliomas: a new direction using combined Ro 038799 (pimonidazole) and SR 2508 (etanidazole). Int J Radiat Oncol Biol Phys 1988; 15: 677-684.
45. Riese NE, Loeffler JS, Wen P, Alexender E, Black PM, Coleman CN. A phase I study of etanidazole and radiotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 1994; 29(3): 617-620.
46. Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ. Enhancement of X-ray-induced DNA damage by pretreatment with halogenated analogs. Int J Radiat Oncol Biol Phys 1987; 13: 733-739.
47. Levin VA, Prados MR, Wara WM et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995; 32(1): 75-83.
48. Phillips TL, Prados MD, Bodell WJ, Levin VA, Uhl V, Gutin PH. Rationale for and experience with clinical trials of halogenated pyrimidines in malignant gliomas: the UCSF/NCOG experience. In: Dewey WC, Edington M, Fry RJM, Hall EJ, Whitmore GF (eds). Radiation Research: A Twentieth-Century Perpesctive. San Diego: Academic Press 1992: 601-606.
49. Hall EJ. Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. Br J Radiol 1972; 45: 81-97.
50. Kelly PJ, Daumas-Duport C, Kispert DB, Kail BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987; 66: 865-874.
51. Bashir R, Hochberg F, Oot R. Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 1988; 23: 27-30.
52. Bernstein M, Laperriere N, Leung P, McKenzie S. Interstitial brachytherapy for malignant brain tumors: preliminary results. Neurosurgery 1990; 26: 371-380.
53. Leibel SA, Gutin PH, Wara WM et al. Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1989; 17: 1129-1139.
54. Loeffler JS, Alexander E, Wen PY, Shea WM. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 1990; 82: 1918-1921.
55. Gutin PH, Prados MD, Phillips TL et al. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG Study 6G-82-2. Int J Radiat Oncol Biol Phys 1991; 21: 601-606.
56. Gutin PH, Leibel SA, Wara WM et al. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125. J Neurosurg 1987; 67: 864-873.
57. Shrieve DC, Alexander E, Wen PY et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995; 36: 275-284.
58. Bernstein M, Laperriere N, Glen J, Leung P, Thomason C, Landon A. Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 1994; 30(5): 1213-1217.
59. Florell RC, Macdonald DR, Irish WD et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 1992; 76: 179-183.
60. Green SB, Shapiro WR, Burger PC et al. A randomized trial of interstitial radiotherapy (RT) boost for newly diagnosed malignant glioma. In: Brain Tumor Cooperative Group (BTCG) trial 8701, American Society of Clinical Oncology, Dallas, TX, 1994: 174.
61. Bernstein M, Laperriere N, Glen J et al. Brachytherapy for malignant glioma: results of a prospective randomized study. Can J Neurol Sci 1997; 24: S21.
62. Anonymous. Consensus statement on stereotactic radiosurgery: quality improvement. Neurosurgery 1994; 34: 193-195.
63. Luxton G, Jozsef G. Single isocenter treatment planning for homogeneous dose delivery to nonspherical targets in multiarc linear accelerator radiosurgery. Int J Radiat Oncol Biol Phys 1995; 31(3): 635-643.
64. Bourland JD. McCollough KP. Static field conformal stereotactic radiosurgery: physical techniques. Int J Radiat Oncol Biol Phys 1994; 28(2): 471-479.
65. Nedzi LA, Kooy HM, Alexander E, Svensson GK, Loeffler JS. Dynamic field shaping for stereotactic radiosurgery: a modeling study. Int J Radiat Oncol Biol Phys 1993; 25(5): 859-869.
66. Gill S. Radiosurgery for brain tumours: is there a proven benefit? Br J Neurosurg 1995; 9: 123-125.
67. Loeffler JS, Alexander E, Shea M et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992; 10(9): 1379-1385.
68. Coffey RJ, Lunsford D, Flickinger JC. The role of radiosurgery in the treatment of malignant brain tumors. Neurosurg Clin N Am 1992; 3: 231-244.
69. Shrieve DC, Alexander E, Wen PY et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995; 36: 275-284.
70. Mehta MP, Masciopinto J, Rozental J et al. Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 1994; 30: 541-549.
71. Engenhart R, Wowra B, Debus J et al. The role of high-dose, single-fraction irradiation in small and large intracranial arteriovenous malformations. Int J Radiat Oncol Biol Phys 1994; 30(3): 521-529.
72. Kondziolka D, Lunsford DL, Claasen D, Pandalai S, Maitz AH, Flickinger JC. Radiobiology of radiosurgery: Part II. The rat C6 glioma model. Neurosurgery 1992; 31(2): 280-288.
73. Agbi CB, Bernstein M, Laperriere N, Leung P, Lumley M. Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int J Radiat Oncol Biol Phys 1992; 23: 321-326.
74. Loeffler JS, Alexander E, Hochberg FH et al. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 1990; 19: 1455-1462.
75. Sneed PK, Gutin PH, Larson DA et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 1994; 29: 719-727.
76. Gutin PH, Bernstein M, Sano Y, Deen DF. Combination therapy with 1, 3-bis(2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy. Neurosurgery 1984; 15(6): 781-786.
77. Bampoe J, Glen J, Mackenzie I, Porter P, Bernstein M. Effect of implant dose/volume and surgical resection on survival in a rat glioma brachytherapy model: implications for brain tumor therapy. Neurosurgery (in press).
78. Lunsford DL, Kondziolka D, Flickinger JC. Stereotactic radiosurgery for benign intracranial tumors. Clin Neurosurg 1993; 40: 475-497.
79. Desai R, Bruce J. Meningiomas of the cranial base. J Neurooncol 1994; 20: 255-279.
80. Duncan W. An evaluation of the results of neutron therapy trials. Acta Oncologica 1994; 33(3): 299-230.
81. Laramore GE, Diener-West M, Griffin TW et al. Randomized neutron dose searching study for malignant gliomas of the brain: results of an RTOG study. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1988; 14: 1093-1102.
82. De Tribolet N, Sawamura Y Non-surgical treatment of brain tumors: rationale, biologic effects, and limitations. In: Crockard A, Hayward R, Hoff JT (eds). Neurosurgery: The Scientific Basis of Clinical Practice, 2nd Edn. Boston: Blackwell, 1992: 571-584.
83. Asbury AK, Ojemann RG, Nielsen SL, Sweet WH. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 1972; 31: 279-293.
84. Goodman GB, Skarsgard LD, Thompson GB, Harrison R, Lam GK, Lugate C. Pion therapy at TRIUMPE Treatment results for astrocytoma grades 3 and 4: a pilot study. Radiother Oncol 1990; 17(1): 21-28.
85. Hug EB, Fitzek MM, Liebsch NJ, Munzenrider JE. Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning. Int J Radiat Oncol Biol Phys 1995; 31 (3) : 467-476.
86. Hoshino T. Therapeutic implications of brain tumor cell kinetics. Natl Cancer Inst Mono 1977; 46: 29-35.
87. Chapman JD, Allalunis-Turner MJ. Cellular and molecular targets in normal tissue radiation injury. In: Gutin PH, Leibel SA, Sheline GE (eds). Radiation Injury to the Nervous System. New York: Raven Press, 1991: 3-15.
88. Bernstein M, Ginsberg H, Glen J. Protection of iodine-125 brachytherapy brain injury in the rat with the 21-aminosteroid U-74389F. Neurosurgery 1992; 31(5): 923-928.
89. Nethersell AB. Biological modifiers and their role in cancer therapy. Ann Acad Med (Sing) 1990; 19(2): 223-234.
90. Mauch P, Constine L, Greenberger J et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31 (5): 1319-1339.
91. Zucali JR. Mechanisms of protection of hematopoietic stem cells from irradiation. Leukemia Lymphoma 1994; 13(1-2): 27-32.
92. Thornton AF, Hegarty TJ, Ten Haken RK et al. Three-dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation. Int J Radiat Oncol Biol Phys 1991; 20(6): 1309-1315.
93. Sandler HM, Radany EH, Greenberg HS, Junck L, Lichter AS. Dose escalation using 3D conformal radiotherapy for high grade astrocytomas. Int J Radiat Oncol Biol Phys 1994;30(suppl).
94. Sneed PK, Lamborn KR, Larson DA et al. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1996; 35(1): 37-44.
95. Kondziolka D, Lunsford DL, Claassen D, Maitz AH, Flickinger JC. Radiobiology of radiosurgery: part I. The normal rat brain model. Neurosurgery 1992; 31(2): 271-279.